D014230Chemicals & DrugsD03.383.129.79960960.934383Triazolesplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMedicine-Infectious Diseases30854922Collins J, Shea K, Parsad S, Plach K, Lee PJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersThe impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. J Oncol Pharm Pract. 2020 Jan; 26(1):5-12.J Oncol Pharm Pract2019-03-09T00:00:002019The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation.32094461Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MALeukemiaIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.Leukemia2020-02-24T00:00:002020Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.32124443Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak ABritish journal of haematologySelinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.Br J Haematol2020-03-02T00:00:002020Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.Medicine-Hematology and OncologyOphthalmology and Visual Science31291985Dama P, Tang M, Fulton N, Kline J, Liu HJournal for immunotherapy of cancerGal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.J Immunother Cancer2019-07-10T00:00:002019Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.34310978Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble GGastroenterologyTVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.Gastroenterology2021-07-23T00:00:002021TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.1.777470.0059318760research area of0.8302920.0063484394subject area forhttps://ophthalmology.uchicago.edu/The University of Chicago Department of Ophthalmologyhttp://retinatoday.com/2010/02/5-questions-with-seenu-m-hariprasad-md/5 QUESTIONS with Seenu M. Hariprasad, MDhttps://ophthalmology.uchicago.edu/news/london-based-architect-and-cyclist-vision-renewedFor London-Based Architect and Cyclist, A Vision RenewedUChicagoOVSUniversity of ChicagoMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorWendyStockwHF9BKIeOfnamXNnYUHhvWD+6g==Wendy Stock41.78927490000000-87.601250000000001502Stock, WendyProfessorSeenuHariprasadSeenu Hariprasad41.78927490000000-87.601250000000002154Hariprasad, SeenuProfessorAndrzejJakubowiak1mhjCqp1G+POmHtvQFPt+2z5/syyp7BaZQ==Andrzej Jakubowiak41.78927490000000-87.601250000000002384Jakubowiak, AndrzejProfessorKathleenMullaneKathleen Mullane41.78927490000000-87.60125000000000635Mullane, KathleenClinical Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessor